Vericel Corporation (VCEL)
| Previous close | 36.00 |
| Open | 35.51 |
| Bid | 32.40 x 1200 |
| Ask | 38.34 x 1300 |
| Day's range | 35.35 - 35.90 |
| 52-week range | 20.98 - 39.90 |
| Volume | |
| Avg. volume | 326,839 |
| Market cap | 1.687B |
| Beta (5Y monthly) | 1.67 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.21 |
| Earnings date | 21 Feb 2024 - 26 Feb 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 42.58 |
Insider MonkeyVericel Corporation (NASDAQ:VCEL) Q3 2023 Earnings Call Transcript
Vericel Corporation (NASDAQ:VCEL) Q3 2023 Earnings Call Transcript November 8, 2023 Vericel Corporation beats earnings expectations. Reported EPS is $-0.08, expectations were $-0.13. Operator: Ladies and gentlemen, thank you for standing by. Welcome to Vericel’s Third Quarter 2023 conference call. At this time, all participants are in a listen-only mode. I would also like remind […]
GlobeNewswireVericel Reports Third Quarter 2023 Financial Results and Raises Full-Year 2023 Financial Guidance
Record Third Quarter Revenue of $45.6 Million, Representing 18% Growth versus Prior Year MACI Revenue Growth of 21% to $37.6 Million Full-Year 2023 Revenue Guidance Raised to $192.5-197.5 Million Conference Call Today at 8:30am Eastern Time CAMBRIDGE, Mass., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today reported financial results and business highlights for the third quarter ended Se
- GlobeNewswire
Vericel to Present at the Stephens Annual Investment Conference
CAMBRIDGE, Mass., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, President and CEO and Joe Mara, CFO will present at the Stephens Annual Investment Conference. The fireside chat will begin at 10:00 a.m. ET (9:00 a.m. CT) on Wednesday, November 15, 2023. A webcast of the presentation will be available on the Investor Relations section of the Vericel Corpo
